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Abstract
Background: To compare the prognostic value of different anatomical and functional metabolic parameters
determined using [18F]FDG-PET/CT with other clinical and pathological prognostic parameters in cervical cancer (CC).
Methods: Thirty-eight patients treated with standard curative doses of chemo-radiotherapy (CRT) underwent pre- and
post-therapy [18F]FDG-PET/CT. [18F]FDG-PET/CT parameters including mean tumor standardized uptake values (SUV),
metabolic tumor volume (MTV) and tumor glycolytic volume (TGV) were measured before the start of CRT.
The post-treatment tumor metabolic response was evaluated. These parameters were compared to other
clinical prognostic factors. Survival curves were estimated by using the Kaplan-Meier method. Cox regression
analysis was performed to determine the independent contribution of each prognostic factor.
Results: After 37 months of median follow-up (range, 12–106), overall survival (OS) was 71 % [95 % confidence
interval (CI), 54–88], disease-free survival (DFS) 61 % [95 % CI, 44–78] and loco-regional control (LRC) 76 %
[95 % CI, 62–90]. In univariate analyses the [18F]FDG-PET/CT parameters unfavorably influencing OS, DFS and
LRC were pre-treatment TGV-cutoff ≥562 (37 vs. 76 %, p = 0.01; 33 vs. 70 %, p = 0.002; and 55 vs. 83 %, p = 0.005,
respectively), mean pre-treatment tumor SUV cutoff ≥5 (57 vs. 86 %, p = 0.03; 36 vs. 88 %, p = 0.004; 65 vs.
88 %, p = 0.04, respectively) and a partial tumor metabolic response after treatment (9 vs. 29 %, p = 0.0008; 0
vs. 83 %, p < 0.0001; 22 vs. 96 %, p < 0.0001, respectively). After multivariate analyses a partial tumor metabolic
response after treatment remained as an independent prognostic factor unfavorably influencing DFS and LRC
(RR 1:7.7, p < 0.0001, and RR 1:22.6, p = 0.0003, respectively) while the pre-treatment TGV-cutoff ≥562 negatively
influenced OS and DFS (RR 1:2, p = 0.03, and RR 1:2.75, p = 0.05).
Conclusions: Parameters capturing the pre-treatment glycolytic volume and metabolic activity of [18F]FDG–positive
disease provide important prognostic information in patients with CC treated with CRT. The post-therapy [18F]FDG-PET/
CT uptake (partial tumor metabolic response) is predictive of disease outcome.
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Background
Cervical cancer (CC) is the second most common
cancer among women in the world and a leading cause of
cancer mortality [1]. Since the publication in 1999 of ran-
domized trials using platinum-based chemotherapy
(PBCT) in patients with locally-advanced cervical cancer
(LACC) and the clinical recommendations announced by
the National Cancer Institute, concurrent radiotherapy
(RT) and cisplatin-based chemotherapy became the
standard management with a significant improvement
in survival rates compared with RT alone [2–6]. More
recently other trials suggested that there might be a
benefit for sequential chemotherapy after standard con-
comitant chemo-radiotherapy (CRT) and this thera-
peutic approach is now being tested in randomized
trials [7, 8]. The gains in survival observed with CRT
have come at a substantial price because both acute
and late morbidities increased with combined modality
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treatment. It is thus expected that intensifying the
PBCT regimen would increase side effects and reduce
the patient’s quality of life. Even with the significant re-
ductions in the risk of CC death observed with CRT,
the absolute gains are small for patients with early tu-
mors, many of whom could have been cured with RT
alone and recurrence rates are still high for patients
with very large or advanced tumors for whom adjuvant
chemotherapy might be of benefit [7]. It is therefore
important to establish accurate predictors of CRT re-
sponse, particularly if adjuvant chemotherapy after pri-
mary CRT should become the new treatment paradigm.
Some clinical and pathological prognostic factors in-
cluding age, histological tumor type, tumor grade, large
tumor size, International Federation of Gynecology and
Obstetrics (FIGO) stage, pelvic and para-aortic lymph
node metastasis, lympho-vascular space invasion (LVSI)
and anemia are currently considered important for sur-
vival and/or treatment outcome [9–11]. By using these
prognostic factors and despite carefully implemented
treatment it is estimated that 30-40 % of patients with
LACC will still recur and eventually die from the dis-
ease. Therefore additional research efforts have concen-
trated on prognostic factors to accurately predict the
prognoses of patients with LACC [12]. Advances in the
understanding of the tumor microenvironment such as
hypoxia [11, 13, 14], interstitial fluid pressure [15, 16],
angiogenesis [17, 18] and the immune landscape [19, 20]
open the window to implement new therapeutic
approaches and to tailor intensified treatment to those
patients considered as having a significant risk of recur-
rence or death. There is a high level of evidence that
18F-labeled fluorodeoxyglucose positron emission tom-
ography [18F]FDG-PET/CT plays an essential role in the
primary evaluation of CC, particularly in evaluating
lymph nodal status and distant metastases, contributing
to precise tumor staging and changes in therapeutic atti-
tudes [21]. [18F]FDG-PET/CT is also important as a pre-
dictor of treatment outcome after CRT [22]. The
maximum standardized uptake value (SUVmax) of the
primary tumor, a semi-quantitative parameter derived
from [18F]FDG-PET/CT, is known to be a significant
prognostic factor in many types of cancers as well as CC
[23–25]. However, this parameter is a single voxel value
and does not reflect the metabolism of the whole tumor.
Other volumetric [18F]FDG-PET/CT parameters such as
average SUV (SUVmean), metabolic tumor volume
(MTV) and total glycolytic activity within the tumor vol-
ume (TGV) are easily acquired using a threshold-based
automatic volume of interest technique [26].
In this study we compared the prognostic values of
various volume-based metabolic parameters including
SUVmax, SUVmean, MTV, and TGV determined using
[18F]FDG-PET/CT with other clinical and pathological
prognostic parameters in patients with LACC treated with
CRT. The purpose of this study was to establish whether
tumor SUV, MTV and TGV add prognostic information
to clinical prognostic factors in patients with LACC.
Methods
After approval by the local ethics committee, we retro-
spectively reviewed the charts of 38 consecutive eligible
patients who presented an intact LACC and were treated
with concomitant cisplatin and RT between 2007 and
2014. Inclusion criteria were pathological diagnosis of
CC, stage IB1-IVA according to the FIGO 2009 defin-
ition. Patients with stage IB1 and IIA1 were considered
for inclusion if they had positive lymph nodes. Patients
were also required to have staging by examination under
anesthesia, [18F]FDG-PET/CT imaging and pelvic mag-
netic resonance imaging (MRI) at diagnosis, a minimum
6-month follow-up and a second [18F]FDG-PET/CT
image three months after completing CRT. Exclusion
criteria were history of previous chemotherapy or RT
and metastatic disease. Patients with positive pelvic/
para-aortic lymph nodes were not considered as FIGO
IVB (metastatic) because these patients can still undergo
a curative cisplatin-based CRT treatment. We thus in-
cluded patients with positive nodes in our analysis.
Data were obtained from the electronic and written
medical records and included age at diagnosis, date of
diagnosis, histology, grade, presence of LVSI, FIGO
stage, presence of positive lymph nodes confirmed by
[18F]FDG-PET/CT, tumor size measured on MRI, tumor
SUVmean, tumor SUVmax, MTV, TGV, body mass index,
complete blood counts (CBC) before treatment (white
blood cells, platelets, hemoglobin), RT dose (including
brachytherapy dose), metabolic tumor response measured
by [18F]FDG-PET/CT at three months post-treatment,
SUVmax, SUVmean, TGV and MTV of tumors at recur-
rence, date and location of recurrence, date of last follow-
up and date of death.
Recurrences were grouped into local (vaginal and/
or cervical recurrences), regional (pelvic/para-aortic
recurrences), and distant (upper abdominal and/or
extra-abdominal).
[18F]FDG-PET/CT acquisition parameters
All patients fasted for at least 6 h before the PET study.
The [18F]FDG-PET/CT was performed 60 min after ad-
ministration of 3.5 MBq/kg [18F]]FDG (Discovery 690FX
TOF; GE Healthcare, Milwaukee, WI) and images (from
the head to proximal thigh) were reconstructed using
time-of-flight and point-spread function information. The
SUV was calculated by correcting for the injected dose of
[18F]-FDG and patient’s body weight. An increase in FDG
uptake above a SUV of 2.5 g/ml was used to define malig-
nancy based on previous publications [27–29].
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[18F]FDG-PET-CT tumor measurements
All PET/CT studies were retrieved from the electronic
archival system and were then reviewed on a worksta-
tion (Velocity Advanced Image Software; Velocity
Medical Solutions, Atlanta, GA), PET, CT, and de-
formable registered PET/CT images were reviewed in
axial, coronal and sagittal planes. For the purposes of
this study the relevant imaging biomarker measure-
ments were tumor SUVmax, SUVmean, MTV and
TGV obtained from the pre-treatment PET. The
SUVmax was defined as the maximum SUV within
the tumor. SUVmean was calculated by computing
the average SUV within a region of interest (tumor).
The MTV was defined as the FDG avid tumor vol-
ume measured bi-dimensionally at the longest diam-
eter. The total glycolytic activity within the tumor
volume or TGV was defined as follows:
MTV  SUVmean;
where MTV is the metabolic tumor volume and SUV-
mean is the mean SUV. Once the primary tumor was
auto-segmented, the software automatically calculated
the SUVmax, SUVmean, MTV, and TGV [26].
Metabolic tumor volume defines the volume of the
tumor on the basis of the distribution of metabolic activ-
ity instead of the traditional CT densities that depend on
electron density of the target. TGV goes a step further
and effectively weighs this volume by its mean metabolic
activity. Hence, a large TGV may reflect a small volume
with high metabolic activity (high SUVmean) or a large
volume with a lower metabolic activity. These two con-
ditions are different and may be related to different
tumor blood supply, microenvironment conditions,
tumor hypoxia, etc. [30]. To better assess the outcome
of these patients, taking into account these two different
conditions, we dichotomized the MTV and the SUV-
mean at the sample median. This dichotomization
allowed us to group patients below or above the variable
in question (group A: patients with MTV below the me-
dian, group B: patients with MTV above the median,
group C: patients with SUV below the median, group D:
patients with SUV above the median). Based on the
MTV and SUV dichotomization, patients were then
stratified in four different categories:
Group A + C: Patients with MTV below the median +
patients with mean SUV below the median
Group A + D: Patients with MTV below the median +
patients with mean SUV above the median
Group B + C: Patients with MTV above the median +
patients with mean SUV below the median
Group B + D: Patients with MTV above the median +
patients with mean SUV above the median
Post-treatment metabolic response was determined
qualitatively using the following definitions: complete
metabolic response (CMR) was defined as absence of
abnormal FDG uptake at sites of abnormal FDG up-
take noted on the pre-treatment [18F]FDG-PET/CT
study. Partial metabolic response (PMR) was defined
as any persistent abnormal FDG uptake at these sites.
Progressive disease (PD) was defined as any new sites
of abnormal FDG uptake that were not present on
the pre-treatment PET [22].
We also obtained the SUVmax, SUVmean, MTV, and
TGV from the [18F]FDG-PET/CT from patients that had
partial metabolic response after chemo-radiotherapy
treatment.
Cisplatin and radiotherapy administration
Chemotherapy consisted of weekly cisplatin (40 mg/m2)
delivered concurrently with RT. Neither induction nor
adjuvant chemotherapy was administered.
Before starting RT treatment, patients underwent a
pelvic computed tomography (CT) scan (planning scan)
with intravenous contrast medium. They were scanned
in a supine position with a head and knee support. For
the CT-planning scan, standard acquisition parameters
were used (tension, 120 kV; tube rotation time 1 s; tube
current, 160 mA; helical acquisition with pitch of 0.938;
reconstructed image thickness, 2 mm). Consortium
guidelines were used to contour the pelvic clinical tar-
get volume (CTV) [31]. According to the same guide-
lines, a 1.5-cm uniform margin was added around the
CTV to obtain the pelvic planning target volume
(PTV). The nodal CTV was delineated according to the
published guidelines, with a 7-mm uniform margin to
obtain the nodal PTV [32]. The small bowel, sigmoid,
rectum, bladder and femoral heads were contoured as
organs at risk. Treatment plans were performed using
the Tomotherapy treatment planning system (Accuray
Inc, Sunnyvale, CA) with a field width of 5 cm and a
pitch of 0.287. Pelvic radiation dose was 45–50.4 Gy in
1.8-Gy daily fractions, in 25–28 fractions. In patients
with positive pelvic or para-aortic nodes, extended field
RT was used to a dose of 45 Gy with a simultaneous in-
tegrated boost to the positive nodes of 60 Gy in 2.4-Gy
per fraction in 25 fractions. Daily image guidance before
each fraction was implemented using the MV fan-beam
CT of Tomotherapy. Patients received 3–4 fractions of
MRI-guided high-dose-rate (HDR) intracavitary brachy-
therapy every 4 days. The prescribed dose was 7 Gy to the
high-risk CTV. Brachytherapy was administered after the
end of external beam RT.
Clinical and imaging follow-ups
Clinical follow-up exams of the patients were performed
weekly during CRT and after the completion of therapy
Herrera et al. Radiation Oncology  (2016) 11:43 Page 3 of 11
as follows: every 3 months until 24 months, every
6 months during years 2–5, and annually thereafter. All
the patients in this series had a [18F]FDG-PET/CT
evaluation at three months following CRT to assess
tumor response. Subsequently follow-up imaging studies
consisted of MRI/CT and/or [18F]FDG-PET/CT if clinic-
ally indicated. Recurrences were biopsy/surgical speci-
men proven in more than 50 % of the cases of recurrent
disease and in the remainder of the cases recurrences
were proved by [18F]FDG-PET/CT.
Statistical considerations
Survival curves were computed using the Kaplan-Meier
method [33]. Time to any event was measured from the
day of diagnosis. Death certificates confirmed date of
deaths. If clinical or pathological evidence of active, re-
current disease was present, deaths were attributed to
CC. The events were death (all causes) for overall sur-
vival (OS) and death (all causes) or relapse for disease-
free survival (DFS). For the loco-regional control (LRC)
rate the event consisted of local or regional relapse.
Confidence intervals (CI) were calculated from stand-
ard errors. In univariate analyses differences between
groups were assessed using the log-rank test.
All variables were dichotomized using cutoffs reported
in the literature when available or the best discriminat-
ing value as determined by recursive partitioning [34].
In multivariate analyses we screened for prognostic
factors with a p-value of less than 0.05 in univariate ana-
lyses by using the Cox regression analysis to define the
independent contribution of each prognostic factor [35].
Unpaired Student’s t test was used to compare means
of two individual groups.
A p value of ≤ 0.05 was considered to be statistically
significant. All data were examined using JMP version
10.0.0 (SAS Institute Inc., Cary, NC).
Results
Patient and tumor characteristics
A total of 38 patients with LACC were identified who ful-
fill the inclusion criteria. Patients’ surgical, pathological
and treatment characteristics are detailed in Table 1. The
median age was 52.5 years (range, 26–83 years). The me-
dian tumor size was 4.5 cm (range, 2–8 cm). The median
body-mass index at diagnosis was 23 (range, 14–42).
The median CBC at baseline was 8.55 · 103/mL (range,
4.6–25.6) for white blood cells; 130 g/dL (range, 71–149)
for hemoglobin; 273.5 · 103/mL (range, 186–819) for
platelets.
The pre-treatment tumors’ average SUVmax, SUVmean,
MTV, and TGV (range) were 17.8 g/mL (4.3–34.6),
4.24 g/mL (2–8.28), 114.16 cm3 (19.73–546.12), and
493.75 (55.83–2991); respectively.
In patients with PMR, the three-months post-
treatment primary tumor’s average SUVmax, SUVmean,
MTV, and TGV (range) were 18.4 g/mL (4–20), 10.38 g/mL
(3.5–17), 43.15 cm3 (6–35.4), 521.64 (72–2496); respectively.
Cisplatin and radiotherapy treatment
All patients received, as planned, 5 cycles of cisplatin
combined with RT. Four patients had cisplatin dose
modifications: 2 because of renal toxicity and 2 be-
cause of leucopenia. In these 4 patients the cisplatin
dose was reduced to 30 mg/m2 and 20 mg/m2 respect-
ively. The median pelvic radiation dose was 45 Gy (range,
45–50.4 Gy). Twenty-two patients received extended-field
RT to the para-aortic lymph nodes. All women received
HDR brachytherapy with a median dose of 28 Gy (range,
21–28 Gy) in 3–4 fractions. No patient experienced delays
or breaks in RT because of short-term toxicity (median
RT duration, 41 days; range, 32–51 days).
Disease outcome
After a median follow-up period of 37 months (range,
6–106 months), the 3-year OS was 71 % (95 % CI,
54–88), DFS 61 % (95 % CI, 44–78) and LRC 76 %
Table 1 Patient and tumor characteristics in 38 patients treated
with cervical cancer treated with chemo-radiotherapy
FIGO stage N = 38 Percent
IB1 2 5.2
IB2 4 10.5
IIA1 6 15.7
IIA2 4 10.5
IIB 15 39.5
IIIA 2 5.2
IIIB 4 10.5
IVA 1 2.6
Histology
Squamous-cell carcinoma 33 87
Adenocarcinoma 5 13
Grade
1 8 21
2 23 60.5
3 7 18.5
Lymph nodal status
Pelvic positive 10 26.3
Pelvic and para-aortic positive 12 31.6
Negative lymph nodes 16 42.1
Lymphovascular space invasion
Positive 26 68.4
Negative 12 31.5
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(95 % CI, 62–90). By the end of follow-up 24 out of 38
(63.15 %) patients were alive and without disease. A total
of 14 patients (36.84 %) experienced a recurrence. Nine
patients had a local recurrence, 3 of them presented also
with regional nodal recurrence and five patients had dis-
tant metastases. All the patients with recurrence died of
CC. The nine patients with local recurrence had a PMR
three months post-primary CRT treatment. For these pa-
tients the [18F]FDG-PET/CT allowed the detection of “in
field” local/regional recurrence which were biopsy proven.
Five of these patients were offered salvaged surgery, and
had a median time since the diagnosis of recurrence to
death of 10.5 months being systemic disease the main
cause of death. The remaining 4 patients with local PMR
presented also systemic disease at the post-treatment
[18F]FDG-PET/CT and the median time since the diagno-
sis of recurrence to death was 6 months.
For the nine patients with PMR three months after
CRT, the mean (±SD) pre-post-therapy TGV were 957
(±1049) and 521 (±773), respectively (unpaired student t
test, p = 0.33), and the mean (±SD) pre-post-therapy MTV
were 126 (±109) and 43 (±46), respectively (unpaired stu-
dent t test, p = 0.05).
In univariate analyses (Table 2) the [18F]FDG-PET/
CT parameters unfavorably influencing OS, DFS and
LRC were pre-treatment TGV-cutoff ≥562 (37 vs. 76 %,
p = 0.01; 33 vs. 70 %, p = 0.002; and 55 vs. 83 %, p = 0.005,
respectively), pre-treatment tumor SUVmean-cutoff ≥5
(57 vs. 86 %, p = 0.03; 36 vs. 88 %, p = 0.004; 65 vs. 88 %,
p = 0.04, respectively), and a partial tumor metabolic
response after treatment (9 vs. 29 %, p = 0.0008; 0 vs. 83 %,
p < 0.0001; 22 vs. 96 %, p < 0.0001, respectively). (Figures 1,
2 and 3). After subgroup analysis based on the MTV and
SUV dichotomization, patient’s in-group A +C and B + C
had significantly better OS, DFS, and LRC than patient’s
in-group A +D and B +D (Table 2 and Fig. 4).
Patients with squamous-cell carcinoma had a statisti-
cally significant better clinical outcome than patients
with adenocarcinomas (OS: 75 vs. 50 %, p = 0.02, DFS 65
vs. 26 %, p = 0.02).
After multivariate analyses a partial tumor metabolic
response after treatment remained as an independent
prognostic factor unfavorably influencing DFS and LRC
(RR 1:7.7, p < 0.0001, and RR 1:22.6, p = 0.0003, respect-
ively) while the pre-treatment TGV-cutoff ≥562 nega-
tively influenced OS and DFS (RR 1:2, p = 0.03, and RR
1:2.75, p = 0.05) (Table 3).
Discussion
We investigated the prognostic values of [18F]FDG-PET/
CT volume-based metabolic parameters and we com-
pared them with other clinical and pathological prognos-
tic factors in LACC patients undergoing CRT. Our study
shows that the pre-treatment TGV, the pre-treatment
tumor SUVmean, and the metabolic response are im-
portant independent prognostic factors for survival
and recurrence. There is an increasing interest in the
utilization of functional parameters in tumor-volume
delineation because metabolic data may significantly
improve the determination of the biologically relevant
volume and the heterogeneity within the tumor. In
our series TGV remained statistically significant as a
predictor of DFS in the multivariate analysis. It is
thus important to differentiate the TGV from other
metabolic parameters evaluated in our study (pre-
treatment SUVmax, SUVmean and MTV). While
standardized uptake value can only represent meta-
bolic activity as a semiquantitative index for tumor
uptake, MTV represents the number of active meta-
bolic tumor cells and the combination of both (TGV)
is a more effective prognostic factor that takes into
account both metabolic activity and tumor volume as
important parameters of tumor response to therapy.
Our results suggest also that the combination of up-
take intensity (SUVmean) and MTV analysis improved
the identification of poor prognosis subtype. It is pos-
sible that at a local level, these tumor differences of
intensity between contiguous voxels represent hetero-
geneity parameters associated with tumor regions of
increased or reduced metabolism determined by dif-
ferent microenvironmental conditions.
The TGV has also been associated with therapeutic re-
sponse and survival in other tumors [36–38]. The TGV
cutoff reported in our series probably reflects the in-
creased recurrence and mortality in patients with large
growing tumor burden (metabolically active fraction).
For these patients it is probable that the volume of the
tumor at presentation determines the mortality within
one or two years, linking tumor aggressiveness with dis-
ease burden. These patients could be those that benefit
from adjuvant intensified PBCT regimens.
Other functional measurements like SUVmean and
SUVmax have been reported as prognostic in CC out-
come in a number of studies. Kidd et al. showed that the
SUVmax of the tumor is a sensitive biomarker for prog-
nosis in patients with uterine CC [23]. In a study where
repetitive PET/CT images of CC patients were taken
during CRT, the SUVmax shows a consistent rate of de-
cline during treatment and declines at a faster rate than
MTV regresses, representing also an earlier tool for pre-
diction of tumor response [39].
One third of patients with LACC will have disease recur-
rence, usually within 2 years of completing treatment. The
most important predictors of disease recurrence include
clinical stage, lymph node status at diagnosis, tumor hist-
ology and early tumor response after treatment [12, 22].
After CRT as definitive treatment of LACC there is suffi-
cient evidence to support the use of [18F]FDG-PET/CT for
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Table 2 Univariate analysis in 38 patients treated with cervical cancer treated with chemo-radiotherapy
Variable n 3-y OS (%) 95 % CI p 3-y DFS (%) 95 % CI p 3-y LRC (%) 95 % CI p
All patients 38 71 54–88 - 61 44–78 - 76 62–90 -
Age (years)
<50 22 41 27–49 63 61–65 72 69–75
0.35 0.7 0.85
>50 16 78 74–82 53 50–56 77 60–94
Tumor size
≥4.5 cm 15 63 61–65 57 55–59 65 63–67
0.5 0.56 0.19
<4.5 cm 23 82 80–84 68 65–71 84 68–100
Stage FIGO 2009
IB1, IIA1, IB2 8 71 68–74 57 55–59 71 67–75
IIA2, IIB 23 74 69–79 0.9 62 60–64 0.84 77 60–94 0.84
IIIA, IIIB, IVA 7 60 56–64 60 56–64 75 71–79
Histology
SCC 33 75 58–92 65 48–82 0.02* 79 65–93
0.02* 0.15
Adenocarcinoma 5 50 45–55 26 21–31 50 45–55
LVSI
Positive 26 63 60–66 58 56–60 72 53–91
0.87 0.62 0.55
Negative 12 65 62–68 66 63–69 83 81–85
Grade
1 3 66 61–71 66 61–71 66 61–71
2 18 56 54–58 0.81 53 52–55 0.92 85 71–99 0.33
3 17 84 82–86 69 67–71 69 67–71
Lymph nodes
Positive 22 55 52–58 60 57–63 76 58–94
0.44 0.66 0.79
Negative 16 74 72–76 62 60–62 76 74–78
Hemoglobin (g/dl)
≥100 34 72 55–89 64 47–81 77 63–91
0.6 0.1 0.46
<100 4 50 43–57 66 61–71 66 61–71
WBC (x103/ml)
≥8.5 19 66 63–69 61 59–63 73 71–75
0.95 0.83 0.44
<8.5 19 65 62–67 61 59–63 79 77–81
Median TGV (cm3)
≥255 19 59 57–61 52 50–54 69 66–72
0.2 0.25 0.38
<255 19 79 77–81 70 68–72 82 65–99
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the assessment of treatment response. The presence of
FDG activity (either persistent or new) can predict survival
outcome. In accordance with our series, a study in which
[18F]FDG-PET/CT was performed 3 months after comple-
tion of treatment showed that a metabolic response was
predictive of long-term survival, with a 3-year survival rate
of 78 % in patients with a CMR, 33 % in patients with a
PMR and 0 % in those with PD. Multivariate analysis in
that study showed that post-treatment response and lymph
node status at diagnosis were the only accurate predictors
of DFS [22]. Standard surveillance programs have proposed
the use of routine physical examinations and patient’s
symptoms education to facilitate early disease recur-
rence. However, by fully exploiting the diagnostic
information derived from pre- and post-treatment
[18F]FDG-PET/CT, patients with adverse metabolic
prognostic factors could potentially benefit from ei-
ther adjuvant systemic therapy or salvage curative
therapy in the case of disease recurrence [40, 41]. In
our study we observed that in patients with local
PMR three-months post CRT, the difference in pre-
post treatment mean TGV were not statistically sig-
nificant (p = 0.33), while the pre-post treatment mean
MTV was significantly reduced after CRT (p = 0.05).
This highlights the fact that even if the tumor meta-
bolic volume reduces its size after CRT, the persistent
high metabolic activity within the tumor may be re-
sponsible for tumor recurrences. This raises the ques-
tion whether dose escalation strategies are more likely
to provide a therapeutic gain.
This study had several limitations including its retro-
spective design and a relatively small sample size of 38
Table 2 Univariate analysis in 38 patients treated with cervical cancer treated with chemo-radiotherapy (Continued)
TGV interquartile range (cm3)
≥562 29 37 27–43 33 30–36 55 52–58
0.01* 0.002* 0.005*
<562 9 76 58–94 70 52–88 83 68–98
Tumor mean SUV (g/ml)
≥5 19 57 54–59 36 33–39 65 63–68
0.03* 0.004* 0.04*
<5 19 86 72–100 88 70–100 88 78–98
Mean tumor SUVmax (g/ml)
≥15 14 61 55–65 53 45–58 62 58–69
0.78 0.51 0.09
<15 24 78 73–83 66 60–72 85 75–90
Three-month post-treatment
PET metabolic response
CMR 29 80 78–82 83 96 93–99
0.0008* 68–98 <0.0001* <0.0001*
PMR 9 30 27–33 0 22 19–25
MTV
≥69 cc 19 58 35–39 63 61–65 73 71–75
0.65 0.47 0.35
<69 cc 19 73 55–61 63 61–65 81 62–100
Group
A + C 8 83 53–100 83 53–100 83 54–100
B + C 11 87 64–100 0.003* 90 73–100 0.0003* 90 73–100 0.03*
A + D 11 68 38–98 50 19–81 78 52–100
B + D 8 0 0 25 0–55 50 16–84
Table abbreviations:
OS Overall survival, DFS Disease-free survival, LRC Loco-regional control, CI Confidence interval, FIGO International Federation of Gynecology and Obstetrics staging
system, TGV Total glycolytic activity within the tumor volume, SUV Standardized uptake value, SUVmax Maximum SUV, MTV Metabolic tumor volume, SCC Squa-
mous cell carcinoma, LVSI Lympho-vascular space invasion, WBC White blood cells, CMR Complete metabolic response, PMR Partial metabolic response
Group categories: Group A + C: Patients with MTV below the median + patients with mean SUV below the median. Group A + D: Patients with MTV below the
median + patients with mean SUV above the median. Group B + C: Patients with MTV above the median + patients with mean SUV below the median. Group B +
D: Patients with MTV above the median + patients with mean SUV above the median
*p-values statistically significant
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patients as well as the long accrual period with con-
sequent variations in treatment protocols according
to each patient’s situation and corresponding physi-
cian’s decision, which might have affected the out-
come of the patients. We used the segmentation
algorithm from only one commercially available
software workstation for image analysis and need to
investigate other segmentation algorithms. Despite
this, our study provides proof-of-concept to support
the clinical value of volumetric functional assess-
ment. Validation in a prospective and larger cohort
of patients is warranted.
Fig. 1 Univariate analysis. [18F]FDG-PET/CT Standard uptake value
(SUV) mean cutoff ≥5 (blue curve) before starting chemo-radiotherapy
unfavorably influenced: a) Overall survival (86 vs. 57 %, p = 0.03),
b) Disease-free survival (88 vs. 36 %, p = 0.004), and c) Locoregional
control (88 vs. 65 %, p = 0.04)
Fig. 2 Univariate analysis. [18F]FDG-PET/CT tumor glycolytic volume
(cutoff ≥562) before starting chemo-radiotherapy unfavorably
(blue curve) influenced: a) Overall survival (37 vs. 76 %, p = 0.01),
b) Disease-free survival (33 vs. 70 %, p = 0.002), and c) Locoregional
control (55 vs. 83 %, p = 0.04)
Herrera et al. Radiation Oncology  (2016) 11:43 Page 8 of 11
Conclusions
In the current study we demonstrated that TGV is one
of the most effective independent prognostic parameters
for disease outcome in LACC patients undergoing CRT.
Fig. 3 Univariate analysis. [18F]FDG-PET/CT partial tumor metabolic
response after treatment unfavorable (blue curve) influenced: a)
Overall survival (9 vs. 29 %, p = 0.0008); b) Disease-free survival (0 vs.
83 %, p < 0.0001); and c) Locoregional control (22 vs. 96 %, p < 0.0001)
Fig. 4 Univariate analysis. Subgroup analysis based on the
dichotomization of MTV and SUVmean at the sample median. In green
group B + C: Patients with MTV above the median + patients with
mean SUV below the median. In red group A + C: Patients with MTV
below the median + patients with mean SUV below the median. In
orange group A + D: Patients with MTV below the median + patients
with mean SUV above the median. In blue group B + D: Patients with
MTV above the median + patients with mean SUV above the median.
a) Overall survival: B + C 87 %, A + C 83 %, A + D 68 %, B + D 0 %;
p < 0.003. b) Disease-free survival: B + C 90 %, A + C 83 %, A + D 50 %,
B + D 25 %; p < 0.0003. c) Locoregional control: B + C 90 %, A + C 83 %,
A + D 78 %, B + D 50 %; p < 0.03
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These findings suggest that combined assessment of the
metabolic activity and volume of the primary tumor
is more effective for prediction of prognosis in CC
than a single parameter alone. These data need to be
validated in a larger cohort of patients. We confirmed
that the post-treatment partial tumor metabolic re-
sponse is predictive of disease outcome, and this
could have significant implications for the use of ad-
juvant as well as salvage therapies in LACC patients
treated with definitive CRT.
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